Review of patient experiences with tezepelumab for severe asthma
Patient Characteristics, Treatment Patterns and Outcomes of Patients Enrolled in the Tezepelumab Patient Access Programme; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres
This study looks at the experiences of around 200 patients with severe asthma who received tezepelumab to see how well it worked for them in real life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | AstraZeneca Industry-sponsored |
| Drugs / interventions | tezepelumab |
| Locations | 6 sites (Birmingham and 5 other locations) |
| Trial ID | NCT06455462 on ClinicalTrials.gov |
What this trial studies
This observational study reviews medical charts of patients with severe asthma who participated in the tezepelumab patient access programme across various NHS acute trusts in the UK. It aims to collect and analyze clinical data retrospectively from approximately 200 patients who received their first dose of tezepelumab between January 1, 2023, and July 19, 2023. The study will utilize electronic case report forms to abstract relevant information from patient health records, focusing on treatment patterns and outcomes. This approach allows for a comprehensive understanding of the real-world effectiveness of tezepelumab without impacting ongoing treatment decisions.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have severe asthma and received their first dose of tezepelumab during the specified timeframe.
Not a fit: Patients who have received any biologic drug for asthma in a clinical trial within the year prior to starting tezepelumab will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness and treatment patterns of tezepelumab in managing severe asthma.
How similar studies have performed: Other studies have shown success with observational approaches in understanding treatment patterns and outcomes in severe asthma, making this study a continuation of established methodologies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients enrolled on the TPAP who received their first dose of tezepelumab between 1st January 2023 and 19th July 2023 * Patients aged ≥18 years at index Exclusion Criteria: * Patients who received any biologic drug for the treatment of asthma in a clinical trial at any time during the 52 weeks prior to the index date.
Where this trial is running
Birmingham and 5 other locations
- Research Site — Birmingham, United Kingdom (Recruiting)
- Research Site — Liverpool, United Kingdom (Recruiting)
- Research Site — London, United Kingdom (Recruiting)
- Research Site — Newcastle, United Kingdom (Recruiting)
- Research Site — Plymouth, United Kingdom (Recruiting)
- Research Site — Southampton, United Kingdom (Recruiting)
Study contacts
- Study coordinator: AstraZeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.